Soligenix, Inc. (SNGX) Thursday reported positive preliminary top-line results from the Phase 2a study of SGX302 for the treatment of mild-to-moderate psoriasis.
In the Cohort 2 of the study, 2 out of 4 patients treated with SGX302 reached a disease status of "Almost Clear" represented by an Investigator Global Assessment (IGA) score of 1, which is considered the standard clinical measure for treatment success in psoriasis.
Additionally, the Psoriasis Activity and Severity Index (PASI) score, another measure of treatment success, for patients in Cohort 2 had a mean drop of about 50% over the 18-week treatment.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.